A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213

BACKGROUND: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bernstein, S. H., Epner, E., Unger, J. M., LeBlanc, M., Cebula, E., Burack, R., Rimsza, L., Miller, T. P., Fisher, R. I.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2013
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660082/
https://ncbi.nlm.nih.gov/pubmed/23504948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt070
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak